CY1107638T1 - Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος - Google Patents

Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος

Info

Publication number
CY1107638T1
CY1107638T1 CY20071100703T CY071100703T CY1107638T1 CY 1107638 T1 CY1107638 T1 CY 1107638T1 CY 20071100703 T CY20071100703 T CY 20071100703T CY 071100703 T CY071100703 T CY 071100703T CY 1107638 T1 CY1107638 T1 CY 1107638T1
Authority
CY
Cyprus
Prior art keywords
factor viii
ligands
factor
complex
way
Prior art date
Application number
CY20071100703T
Other languages
Greek (el)
English (en)
Inventor
Marc G Jacquemin
Jean-Marie R Saint-Remy
Original Assignee
D. Collen Research Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916450.1A external-priority patent/GB9916450D0/en
Application filed by D. Collen Research Foundation Vzw filed Critical D. Collen Research Foundation Vzw
Publication of CY1107638T1 publication Critical patent/CY1107638T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20071100703T 1999-07-14 2007-05-24 Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος CY1107638T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14389199P 1999-07-14 1999-07-14
GBGB9916450.1A GB9916450D0 (en) 1999-07-14 1999-07-14 Ligands for use in therapeutic compounds for the treatment of hemostasis disorders
EP00949329A EP1194528B1 (en) 1999-07-14 2000-07-13 Monoclonal antibody for factor VIII, which even when present in molar excess inactivates factor VIII only in part and a method for producing such an antibody

Publications (1)

Publication Number Publication Date
CY1107638T1 true CY1107638T1 (el) 2013-04-18

Family

ID=26315767

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100703T CY1107638T1 (el) 1999-07-14 2007-05-24 Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος

Country Status (11)

Country Link
EP (1) EP1194528B1 (enExample)
JP (2) JP4297207B2 (enExample)
AT (1) ATE356201T1 (enExample)
AU (1) AU781638B2 (enExample)
CA (1) CA2381125C (enExample)
CY (1) CY1107638T1 (enExample)
DE (1) DE60033814T2 (enExample)
DK (1) DK1194528T3 (enExample)
ES (1) ES2283308T3 (enExample)
PT (1) PT1194528E (enExample)
WO (1) WO2001004269A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
ES2346189T3 (es) 2001-01-11 2010-10-13 Life Sciences Research Partners Vzw Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada.
DE60230037D1 (de) * 2001-06-12 2009-01-08 Chemo Sero Therapeut Res Inst Humanantikörper gegen blutgerinnungsfaktor viii
EP1388544A1 (en) 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
JP4934796B2 (ja) * 2003-08-14 2012-05-16 トロンボジェニクス・ナムローゼ・フエンノートシャップ 可変抗体
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2616902A1 (en) * 2005-07-29 2007-02-15 Life Sciences Research Partners Vzw Human inhibitory anti-factor viii antibodies binding to the a2 domain
FR2892724B1 (fr) 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
JP2019507746A (ja) 2016-03-10 2019-03-22 オクシュリオン エヌブイ 胎盤増殖因子のアンタゴナイズによる後眼部線維症の阻害
CA3062238A1 (en) * 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
WO2001004269A1 (en) 2001-01-18
AU781638B2 (en) 2005-06-02
JP2003504045A (ja) 2003-02-04
EP1194528A1 (en) 2002-04-10
CA2381125A1 (en) 2001-01-18
ES2283308T3 (es) 2007-11-01
DE60033814T2 (de) 2007-11-08
JP4297207B2 (ja) 2009-07-15
AU6273000A (en) 2001-01-30
JP4297225B2 (ja) 2009-07-15
EP1194528B1 (en) 2007-03-07
PT1194528E (pt) 2007-05-31
DE60033814D1 (de) 2007-04-19
CA2381125C (en) 2013-04-23
JP2008295455A (ja) 2008-12-11
ATE356201T1 (de) 2007-03-15
DK1194528T3 (da) 2007-07-09

Similar Documents

Publication Publication Date Title
DK1194528T3 (da) Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
Eichler et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A
Boggio et al. Acquired hemophilia
Zacharski et al. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding
ATE493148T1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
Ortel Clinical and laboratory manifestations of anti-factor V antibodies
HUS1600041I1 (hu) VII-es véralvadási faktor-FC kiméra proteinek hemosztázis rendellenesség kezelésére
Panyutich et al. Identification of defensin binding to C1 complement
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY1118363T1 (el) Αντισωματα που ανοσοειδικως συνδεονται προς blys
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
PT833911E (pt) Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
Ni et al. Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets
Lin et al. Leptospira immunoglobulin‐like protein B (LigB) binding to the C‐terminal fibrinogen αC domain inhibits fibrin clot formation, platelet adhesion and aggregation
Mizumachi et al. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis
Ljung Prevention and management of bleeding episodes in children with hemophilia
Doolittle et al. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin
EP1544214A4 (en) Non-neutralizing anti-aPC antibodies
Hansen et al. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz–type protease inhibitor 2 domain of tissue factor pathway inhibitor
Bovenschen et al. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding‐site for low‐density lipoprotein receptor‐related protein within the A2 domain
KR102469621B1 (ko) 혈장 단백질에 접합된 헤파린을 포함하는 치료용 apac 분자
RU2015143696A (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АНТИТРОМБИНА β
Naik et al. Application of “ATTEMPTS” for drug delivery
Lollar Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor